Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abetimus Sodium in SLE
NCT00390091Phase 2Withdrawn
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Sep 2006
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of abetimus sodium in systemic lupus erythematosus (SLE), sponsored by La Jolla Pharmaceutical Company. Planned start Sep 2006; status: withdrawn.
02
Drugs
abetimus sodium
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00390091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390091.